Prognostic relevance of Wilms tumor 1 (WT1) gene mutation in-patient with acute myeloid leukemia

• Main Authors: SALAHA AREF, Solafa El Sharawy, Emaad Azmy, Mohamed Sabry, Dalia Abdel Raouf
• Format: Article
• Language: English
• Published: PAGEPress Publications 2014-08-01
• Series: Mediterranean Journal of Hematology and Infectious Diseases
• Subjects: Leukemia
• Online Access: https://mjhid.org/index.php/mjhid/article/view/1725
• ISSN: 2035-3006

This study aimed to assess the prognostic influences of Wilms’ tumor 1 (WT1) gene mutations in cytogenetically normal acute myeloid leukemia (CN-AML)  among Egyptian patients.      Exons 7 of WT1 was screened for mutations in samples from 82 CN-AML patients out of 203 newly diagnosed AML patients, using a high-resolution capillary electrophoresis.     Seven out of 82 AML patients (8.3%) harbored WT1 mutations. There was no significant difference between the  mutant WT1  and wild type AML patients  as regard age, sex, French-American-British subtypes and the prevalence of success of induction remission therapy (P < 0.5).  AML patients with  mutant WT1  had shorter overall survival (OS)  as compared   to those patients  with  wild WT1  (HR= 1.38; 95%; CI 4.79 - 6.86; P = 0.004). In conclusion, CN-AML patients with WT1 gene mutation have poor clinical outcome. We recommend testing the WT1 mutations as part of molecularly based risk assessment and risk-adapted treatment stratification of patients with CN-AML.